

1                                    **CANCEROUS DISEASE MODIFYING ANTIBODIES**

2    **Reference to Related Applications:**

3                    This application is a continuation-in-part of application S.N. 10/413,755, filed March  
4    31, 2003, which is a continuation-in-part of S.N. 09/727,361, filed November 29, 2000, which  
5    is a continuation-in-part of application S.N. 09/415,278, filed October 8, 1999, now U.S.  
6    Patent 6,180,357 B1, the contents of each of which are herein incorporated by reference.

7    **Field of the Invention:**

8                    This invention relates to the isolation and production of cancerous disease modifying  
9    antibodies (CDMAB) and to the use of these CDMAB in therapeutic and diagnostic processes,  
10   optionally in combination with one or more chemotherapeutic agents. The invention further  
11   relates to binding assays which utilize the CDMAB of the instant invention.

12   **Background of the Invention:**

13                   Each individual who presents with cancer is unique and has a cancer that is as different  
14   from other cancers as that person's identity. Despite this, current therapy treats all patients  
15   with the same type of cancer, at the same stage, in the same way. At least 30 percent of these  
16   patients will fail the first line therapy, thus leading to further rounds of treatment and the  
17   increased probability of treatment failure, metastases, and ultimately, death. A superior  
18   approach to treatment would be the customization of therapy for the particular individual. The  
19   only current therapy that lends itself to customization is surgery. Chemotherapy and radiation  
20   treatment cannot be tailored to the patient, and surgery by itself, in most cases is inadequate for

1 producing cures.

2 With the advent of monoclonal antibodies, the possibility of developing methods for  
3 customized therapy became more realistic since each antibody can be directed to a single  
4 epitope. Furthermore, it is possible to produce a combination of antibodies that are directed to  
5 the constellation of epitopes that uniquely define a particular individual's tumor.

6 Having recognized that a significant difference between cancerous and normal cells is  
7 that cancerous cells contain antigens that are specific to transformed cells, the scientific  
8 community has long held that monoclonal antibodies can be designed to specifically target  
9 transformed cells by binding specifically to these cancer antigens; thus giving rise to the belief  
10 that monoclonal antibodies can serve as "Magic Bullets" to eliminate cancer cells.

11 Monoclonal antibodies isolated in accordance with the teachings of the instantly  
12 disclosed invention have been shown to modify the cancerous disease process in a manner  
13 which is beneficial to the patient, for example by reducing the tumor burden, and will  
14 variously be referred to herein as cancerous disease modifying antibodies (CDMAB) or "anti-  
15 cancer" antibodies.

16 At the present time, the cancer patient usually has few options of treatment. The  
17 regimented approach to cancer therapy has produced improvements in global survival and  
18 morbidity rates. However, to the particular individual, these improved statistics do not  
19 necessarily correlate with an improvement in their personal situation.

20 Thus, if a methodology was put forth which enabled the practitioner to treat each tumor  
21 independently of other patients in the same cohort, this would permit the unique approach of  
22 tailoring therapy to just that one person. Such a course of therapy would, ideally, increase the

1 rate of cures, and produce better outcomes, thereby satisfying a long-felt need.

2 Historically, the use of polyclonal antibodies has been used with limited success in the  
3 treatment of human cancers. Lymphomas and leukemias have been treated with human  
4 plasma, but there were few prolonged remission or responses. Furthermore, there was a lack  
5 of reproducibility and no additional benefit compared to chemotherapy. Solid tumors such as  
6 breast cancers, melanomas and renal cell carcinomas have also been treated with human blood,  
7 chimpanzee serum, human plasma and horse serum with correspondingly unpredictable and  
8 ineffective results.

9 There have been many clinical trials of monoclonal antibodies for solid tumors. In the  
10 1980s there were at least 4 clinical trials for human breast cancer which produced only 1  
11 responder from at least 47 patients using antibodies against specific antigens or based on tissue  
12 selectivity. It was not until 1998 that there was a successful clinical trial using a humanized  
13 anti-her 2 antibody in combination with cisplatin. In this trial 37 patients were accessed for  
14 responses of which about a quarter had a partial response rate and another half had minor or  
15 stable disease progression.

16 The clinical trials investigating colorectal cancer involve antibodies against both  
17 glycoprotein and glycolipid targets. Antibodies such as 17-1A, which has some specificity for  
18 adenocarcinomas, had undergone Phase 2 clinical trials in over 60 patients with only 1 patient  
19 having a partial response. In other trials, use of 17-1A produced only 1 complete response and  
20 2 minor responses among 52 patients in protocols using additional cyclophosphamide. Other  
21 trials involving 17-1A yielded results that were similar. The use of a humanized murine  
22 monoclonal antibody initially approved for imaging also did not produce tumor regression. To

1 date there has not been an antibody that has been effective for colorectal cancer. Likewise  
2 there have been equally poor results for lung, brain, ovarian, pancreatic, prostate, and stomach  
3 cancers. There has been some limited success in the use of anti-GD3 monoclonal antibody for  
4 melanoma. Thus, it can be seen that despite successful small animal studies that are a  
5 prerequisite for human clinical trials, the antibodies that have been tested thus far, have been  
6 for the most part, ineffective.

7 Prior Patents:

8 U.S. Patent No. 5,750,102 discloses a process wherein cells from a patient's tumor are  
9 transfected with MHC genes which may be cloned from cells or tissue from the patient. These  
10 transfected cells are then used to vaccinate the patient.

11 U.S. Patent No. 4,861,581 discloses a process comprising the steps of obtaining  
12 monoclonal antibodies that are specific to an internal cellular component of neoplastic and  
13 normal cells of the mammal but not to external components, labeling the monoclonal antibody,  
14 contacting the labeled antibody with tissue of a mammal that has received therapy to kill  
15 neoplastic cells, and determining the effectiveness of therapy by measuring the binding of the  
16 labeled antibody to the internal cellular component of the degenerating neoplastic cells. In  
17 preparing antibodies directed to human intracellular antigens, the patentee recognizes that  
18 malignant cells represent a convenient source of such antigens.

19 U.S. Patent No. 5,171,665 provides a novel antibody and method for its production.  
20 Specifically, the patent teaches formation of a monoclonal antibody which has the property of  
21 binding strongly to a protein antigen associated with human tumors, e.g. those of the colon and  
22 lung, while binding to normal cells to a much lesser degree.

1 U.S. Patent No. 5,484,596 provides a method of cancer therapy comprising surgically  
2 removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor  
3 cells, irradiating the tumor cells to be viable but non-tumorigenic, and using these cells to  
4 prepare a vaccine for the patient capable of inhibiting recurrence of the primary tumor while  
5 simultaneously inhibiting metastases. The patent teaches the development of monoclonal  
6 antibodies which are reactive with surface antigens of tumor cells. As set forth at col. 4, lines  
7 45 et seq., the patentees utilize autochthonous tumor cells in the development of monoclonal  
8 antibodies expressing active specific immunotherapy in human neoplasia.

9 U.S. Patent No. 5,693,763 teaches a glycoprotein antigen characteristic of human  
10 carcinomas is not dependent upon the epithelial tissue of origin.

11 U.S. Patent No. 5,783,186 is drawn to anti-Her2 antibodies which induce apoptosis in  
12 Her2 expressing cells, hybridoma cell lines producing the antibodies, methods of treating  
13 cancer using the antibodies and pharmaceutical compositions including said antibodies.

14 U.S. Patent No. 5,849,876 describes new hybridoma cell lines for the production of  
15 monoclonal antibodies to mucin antigens purified from tumor and non-tumor tissue sources.

16 U.S. Patent No. 5,869,268 is drawn to a method for generating a human lymphocyte  
17 producing an antibody specific to a desired antigen, a method for producing a monoclonal  
18 antibody, as well as monoclonal antibodies produced by the method. The patent is particularly  
19 drawn to the production of an anti-HD human monoclonal antibody useful for the diagnosis  
20 and treatment of cancers.

21 U.S. Patent No. 5,869,045 relates to antibodies, antibody fragments, antibody  
22 conjugates and single chain immunotoxins reactive with human carcinoma cells. The

1 mechanism by which these antibodies function is two-fold, in that the molecules are reactive  
2 with cell membrane antigens present on the surface of human carcinomas, and further in that  
3 the antibodies have the ability to internalize within the carcinoma cells, subsequent to binding,  
4 making them especially useful for forming antibody-drug and antibody-toxin conjugates. In  
5 their unmodified form the antibodies also manifest cytotoxic properties at specific  
6 concentrations.

7 U.S. Patent No. 5,780,033 discloses the use of autoantibodies for tumor therapy and  
8 prophylaxis. However, this antibody is an anti-nuclear autoantibody from an aged mammal. In  
9 this case, the autoantibody is said to be one type of natural antibody found in the immune  
10 system. Because the autoantibody comes from "an aged mammal", there is no requirement that  
11 the autoantibody actually comes from the patient being treated. In addition the patent discloses  
12 natural and monoclonal anti-nuclear autoantibody from an aged mammal, and a hybridoma cell  
13 line producing a monoclonal anti-nuclear autoantibody.

14 Summary of the Invention:

15 The instant inventors have previously been awarded U.S. Patent 6,180,357, entitled  
16 "Individualized Patient Specific Anti-Cancer Antibodies" directed to a process for selecting  
17 individually customized anti-cancer antibodies which are useful in treating a cancerous  
18 disease. For the purpose of this document, the terms "antibody" and "monoclonal antibody"  
19 (mAb) may be used interchangeably and refer to intact immunoglobulins produced by  
20 hybridomas, immunoconjugates and, as appropriate, immunoglobulin fragments and  
21 recombinant proteins derived from immunoglobulins, such as chimeric and humanized  
22 immunoglobulins, F(ab') and F(ab')<sub>2</sub> fragments, single-chain antibodies, recombinant

1 immunoglobulin variable regions (Fv)s etc. Furthermore, it is within the purview of this  
2 invention to conjugate standard chemotherapeutic modalities, e.g. radionuclides, with the  
3 CDMAB of the instant invention, thereby focusing the use of said chemotherapeutics. The  
4 CDMAB can also be conjugated to toxins, cytotoxic moieties or enzymes e.g. biotin  
5 conjugated enzymes.

6 This application utilizes the method for producing patient specific anti-cancer  
7 antibodies as taught in the '357 patent for isolating hybridoma cell lines which encode for  
8 cancerous disease modifying monoclonal antibodies. These antibodies can be made  
9 specifically for one tumor and thus make possible the customization of cancer therapy. Within  
10 the context of this application, anti-cancer antibodies having either cell-killing (cytotoxic) or  
11 cell-growth inhibiting (cytostatic) properties will hereafter be referred to as cytotoxic. These  
12 antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat  
13 tumor metastases.

14 The prospect of individualized anti-cancer treatment will bring about a change in the  
15 way a patient is managed. A likely clinical scenario is that a tumor sample is obtained at the  
16 time of presentation, and banked. From this sample, the tumor can be typed from a panel of  
17 pre-existing cancerous disease modifying antibodies. The patient will be conventionally  
18 staged but the available antibodies can be of use in further staging the patient. The patient can  
19 be treated immediately with the existing antibodies and/or a panel of antibodies specific to the  
20 tumor can be produced either using the methods outlined herein or through the use of phage  
21 display libraries in conjunction with the screening methods herein disclosed. All the  
22 antibodies generated will be added to the library of anti-cancer antibodies since there is a  
23 possibility that other tumors can bear some of the same epitopes as the one that is being

1 treated. The antibodies produced according to this method  
2 may be useful to treat cancerous disease in any number of patients who have cancers that bind  
3 to these antibodies.

4 Using substantially the process of US 6,180,370, the mouse monoclonal antibody  
5 H460-16-2 was obtained following immunization of mice with cells from a patient's lung  
6 tumor biopsy. The H460-16-2 antigen was expressed on the cell surface of a broad range of  
7 human cell lines from different tissue origins. The breast cancer cell line MDA-MB-231 (MB-  
8 231) was only 1 of 2 cancer cell lines tested that was susceptible to the cytotoxic effects of  
9 H460-16-2.

10 The result of H460-16-2 cytotoxicity against MB-231 cells in culture was further  
11 extended by its anti-tumor activity towards these cells when transplanted into mice. In an *in*  
12 *vivo* model of breast cancer, the human MB-231 cells were implanted underneath the skin at  
13 the scruff of the neck of immunodeficient mice, as they are incapable of rejecting the human  
14 tumor cells due to a lack of certain immune cells. Pre-clinical xenograft tumor models are  
15 considered valid predictors of therapeutic efficacy. Xenografts in mice grow as solid tumors  
16 developing stroma, central necrosis and neo-vasculature. The mammary tumor cell line MB-  
17 231 has been evaluated as an *in vivo* xenograft model in immuno-deficient mice. The good  
18 engraftment or 'take-rate' of the MB-231 tumors and the sensitivity of the tumors to standard  
19 chemotherapeutic agents have characterized it as a suitable model. The parental cell line and  
20 variants of the cell line have been used in xenograft tumor models to evaluate a wide range of  
21 therapeutic agents.

22 In the preventative *in vivo* model of human breast cancer, H460-16-2 was given to mice



1 one day prior to implantation of tumor cells followed by weekly injections for a period of 7  
2 weeks. H460-16-2 treatment was significantly ( $p<0.0001$ ) more effective in suppressing tumor  
3 growth during the treatment period than an isotype control antibody, which was identical to  
4 H460-16-2 in structure and size but incapable of binding MB-231 cells. At the end of the  
5 treatment phase, mice given H460-16-2 had tumors that grew to only 1.3 percent of the control  
6 group. During the post treatment follow-up period, the treatment effects of H460-16-2 were  
7 sustained and the mean tumor volume in the treated groups continued to be significantly  
8 smaller than controls until the end of the measurement phase. Using survival as a measure of  
9 antibody efficacy, it was estimated that the risk of dying in the H460-16-2 treatment group was  
10 about 71 percent of the antibody buffer control group ( $p=0.028$ ) at 70 days post-treatment.  
11 These data demonstrated that H40-16-2 treatment conferred a survival benefit compared to the  
12 control-treated groups. H460-16-2 treatment appeared safe, as it did not induce any signs of  
13 toxicity, including reduced body weight and clinical distress. Thus, H460-16-2 treatment was  
14 efficacious as it both delayed tumor growth and enhanced survival compared to the control-  
15 treated groups in a well-established model of human breast cancer. These results were also  
16 reproducible as similar findings were observed in another study of this kind and suggest its  
17 relevance and benefit to treatment of people with cancer.

18 Besides the preventative *in vivo* tumor model of breast cancer, H460-16-2  
19 demonstrated anti-tumor activity against MB-231 cells in an established *in vivo* tumor model.  
20 In this xenograft tumor model, MB-231 breast cancer cells were transplanted subcutaneously  
21 into immunodeficient mice such that the tumor reached a critical size before antibody  
22 treatment. Treatment with H460-16-2 was compared to the standard chemotherapeutic drug,  
23 cisplatin, and it was shown that the cisplatin and H460-16-2 treatment groups had significantly

1 (p<0.001) smaller mean tumor volumes compared with groups treated with either antibody  
2 dilution buffer or the isotype control antibody. H460-16-2 treatment mediated tumor  
3 suppression that was approximately two-thirds that of cisplatin chemotherapy but without the  
4 significant weight loss (p<0.003) and clinical distress observed with cisplatin. The anti-tumor  
5 activity of H460-16-2 and its minimal toxicity make it an attractive anti-cancer therapeutic  
6 agent.

7 In the post-treatment period, H460-16-2 showed a significant survival benefit (p<0.02)  
8 as the risk of dying in the H460-16-2 group was about half of that in the isotype control  
9 antibody group at >70 days after treatment. The observed survival benefit continued on at 120  
10 days post-treatment where 100 percent of the isotype control and cisplatin treated mice had  
11 died compared to 67 percent of the H460-16-2 treatment group. H460-16-2 maintained tumor  
12 suppression by delaying tumor growth by 26 percent compared to the isotype control antibody  
13 group. At 31 days post treatment, H460-16-2 limited tumor size by reducing tumor growth by  
14 48 percent compared to the isotype control group, which is comparable to the 49 percent  
15 reduction observed at the end of the treatment. In the established tumor model of breast  
16 cancer, these results indicate the potential of H460-16-2 to maintain tumor suppression  
17 beyond the treatment phase and demonstrates the ability of the antibody to reduce the tumor  
18 burden and enhance survival in a mammal.

19 By immunohistochemistry (IHC) staining, sections of mouse tissues from multiple  
20 organs were stained with H460-16-2 to localize the H460-16-2 antigen within individual cell  
21 types of various tissues. Consistent with the tumor suppressive effects of H460-16-2 against  
22 MB-231 cells *in vivo*, the H460-16-2 antigen was strongly expressed on sections of tumor  
23 tissue harvested from untreated mice subcutaneously implanted with MB-231 cells.

1 Expression of the H460-16-2 antigen in normal mouse tissues is required for supporting the  
2 mouse as an appropriate model of toxicity for H460-16-2. It was observed that the H460-16-2  
3 antigen had a limited expression pattern in the mouse as it was only expressed in the kidney  
4 and ovary. In order to validate the mouse as a suitable model for toxicity, there needs to be  
5 similar antigen expression in normal human tissue.

6 For clinical trials and to validate an appropriate animal model for toxicity, the  
7 specificity of H460-16-2 towards normal human tissues was determined. By IHC staining with  
8 H460-16-2, the majority of the tissues failed to express the H460-16-2 antigen, including the  
9 vital organs, such as the liver, kidney, heart, and lung. H460-16-2 stained the skin, ureter,  
10 stomach and prostate, and strongly stained the salivary gland. Results from tissue staining  
11 indicated that H460-16-2 showed restricted binding to various cell types but had binding to  
12 infiltrating macrophages, lymphocytes, and fibroblasts. Therefore, the data indicate that the  
13 mouse is probably not the best model for toxicity since that although both the mouse and  
14 human show limited H460-16-2 tissue expression; the tissues positive for staining are not the  
15 same between the two species.

16 Localization of the H460-16-2 antigen and its prevalence within breast cancer patients  
17 is important in assessing the benefits of H460-16-2 immunotherapy to patients and designing  
18 effective clinical trials. To address H460-16-2 antigen expression in breast tumors from  
19 cancer patients, tumor tissue samples from 50 individual breast cancer patients were screened  
20 for expression of the H460-16-2 antigen. The results of the study showed that 64 percent of  
21 tissue samples stained positive for the H460-16-2 antigen. Expression of H460-16-2 within  
22 patient samples appeared specific for cancer cells as staining was restricted towards malignant  
23 cells. In contrast, H460-16-2 stained 2 of 9 samples of normal tissue from breast cancer

1 patients. Breast tumor expression of the H460-16-2 antigen appeared to be mainly localized to  
2 the cell membrane of malignant cells, making it an attractive target for therapy. H460-16-2  
3 expression was further evaluated based on breast tumor expression of the receptors for the  
4 hormones estrogen and progesterone, which play an important role in the development,  
5 treatment, and prognosis of breast tumors. No correlation was apparent between expression of  
6 the H460-16-2 antigen and expression of the receptors for either estrogen or progesterone.  
7 When tumors were analyzed based on their stage, or degree to which the cancer advanced,  
8 results suggested a trend towards greater positive expression with higher tumor stage, but the  
9 results were limited by the small sample size.

10 To further extend the potential therapeutic benefit of H460-16-2, the frequency and  
11 localization of the antigen within various human cancer tissues was determined. Several  
12 cancer types, besides breast, were positive for the H460-16-2 antigen. The positive human  
13 cancer types included skin (1/2), lung (4/4), liver (2/3), stomach (4/5) and kidney (3/3). Some  
14 cancers did not express the antigen; these included ovary (0/3), adrenal gland (0/2) and small  
15 intestine (0/1). As with human breast tumor tissue, localization occurred predominately on the  
16 membrane of tumor cells. So, in addition to the H460-16-2 antibody binding to cancer cell  
17 lines *in vitro*, there is evidence that the antigen is expressed in humans, and on multiple types  
18 of cancers. In toto, this data demonstrates that the H460-16-2 antigen is a cancer associated  
19 antigen and is expressed in humans, and is a pathologically relevant cancer target. Further, this  
20 data also demonstrates the binding of the H460-16-2 antibody to human cancer tissues, and  
21 can be used appropriately for assays that can be diagnostic, predictive of therapy, or  
22 prognostic. In addition, the cell membrane localization of this antigen is indicative of the  
23 cancer status of the cell due to the lack of expression of the antigen in most non-malignant

1 cells, and this observation permits the use of this antigen, its gene or derivatives, its protein or  
2 its variants to be used for assays that can be diagnostic, predictive of therapy, or prognostic.

3 Preliminary data indicate that the antigen recognized by H460-16-2 could be a variant  
4 of the tumor rejection antigen known as the 96 kDa heat shock protein (gp96). This is  
5 supported by biochemical studies showing that monoclonal antibodies reactive against gp96  
6 identify proteins that were bound to H460-16-2. By IHC analysis of mouse tissues using  
7 H460-16-2 and anti-gp96 antibodies, the gp96 antigen appeared to be more widely expressed  
8 than the H460-16-2 antigen. These results were similar to those for IHC staining of normal  
9 human tissues as the H460-16-2 antigen was expressed on a smaller subset of cells compared  
10 to the gp96 antigen. IHC analysis of human breast tumor tissues indicated that the gp96  
11 antigen was more prevalent with approximately 84 percent of samples staining positive with  
12 the anti-gp96 antibody. The gp96 antigen was also expressed differently than H460-16-2 as it  
13 showed both high cytoplasmic and cell membrane localization. These results thus suggest that  
14 H460-16-2 may be a variant of gp96.

15 In all, this invention teaches the use of the H460-16-2 antigen as a target for a  
16 therapeutic agent, that when administered can reduce the tumor burden of a cancer expressing  
17 the antigen in a mammal, and can also lead to a prolonged survival of the treated mammal.  
18 This invention also teaches the use of a CDMAB (H460-16-2), and its derivatives, to target its  
19 antigen to reduce the tumor burden of a cancer expressing the antigen in a mammal, and to  
20 prolong the survival of a mammal bearing tumors that express this antigen. Furthermore, this  
21 invention also teaches the use of detecting the H460-16-2 antigen in cancerous cells that can  
22 be useful for the diagnosis, prediction of therapy, and prognosis of mammals bearing tumors  
23 that express this antigen.

1           If a patient is refractory to the initial course of therapy or metastases develop, the  
2 process of generating specific antibodies to the tumor can be repeated for re-treatment.  
3 Furthermore, the anti-cancer antibodies can be conjugated to red blood cells obtained from that  
4 patient and re-infused for treatment of metastases. There have been few effective treatments  
5 for metastatic cancer and metastases usually portend a poor outcome resulting in death.  
6 However, metastatic cancers are usually well vascularized and the delivery of anti-cancer  
7 antibodies by red blood cells can have the effect of concentrating the antibodies at the site of  
8 the tumor. Even prior to metastases, most cancer cells are dependent on the host's blood  
9 supply for their survival and anti-cancer antibody conjugated to red blood cells can be effective  
10 against *in situ* tumors as well. Alternatively, the antibodies may be conjugated to other  
11 hematogenous cells, e.g. lymphocytes, macrophages, monocytes, natural killer cells, etc.

12           There are five classes of antibodies and each is associated with a function that is  
13 conferred by its heavy chain. It is generally thought that cancer cell killing by naked  
14 antibodies are mediated either through antibody-dependent cell-mediated cytotoxicity (ADCC)  
15 or complement-dependent cytotoxicity (CDC). For example murine IgM and IgG2a antibodies  
16 can activate human complement by binding the C-1 component of the complement system  
17 thereby activating the classical pathway of complement activation which can lead to tumor  
18 lysis. For human antibodies, the most effective complement activating antibodies are generally  
19 IgM and IgG1. Murine antibodies of the IgG2a and IgG3 isotype are effective at recruiting  
20 cytotoxic cells that have Fc receptors which will lead to cell killing by monocytes,  
21 macrophages, granulocytes and certain lymphocytes. Human antibodies of both the IgG1 and  
22 IgG3 isotype mediate ADCC.

1 Another possible mechanism of antibody mediated cancer killing may be through the  
2 use of antibodies that function to catalyze the hydrolysis of various chemical bonds in the cell  
3 membrane and its associated glycoproteins or glycolipids, so-called catalytic antibodies.

4 There are two additional mechanisms of antibody mediated cancer cell killing which  
5 are more widely accepted. The first is the use of antibodies as a vaccine to induce the body to  
6 produce an immune response against the putative antigen that resides on the cancer cell. The  
7 second is the use of antibodies to target growth receptors and interfere with their function or to  
8 down regulate that receptor so that effectively its function is lost.

9 Accordingly, it is an objective of the invention to utilize a method for producing  
10 cancerous disease modifying antibodies from cells derived from a particular individual which  
11 are cytotoxic with respect to cancer cells while simultaneously being relatively non-toxic to  
12 non-cancerous cells, in order to isolate hybridoma cell lines and the corresponding isolated  
13 monoclonal antibodies and antigen binding fragments thereof for which said hybridoma cell  
14 lines are encoded.

15 It is an additional objective of the invention to teach CDMAB and antigen binding  
16 fragments thereof.

17 It is a further objective of the instant invention to produce CDMAB whose cytotoxicity  
18 is mediated through ADCC.

19 It is yet an additional objective of the instant invention to produce CDMAB whose  
20 cytotoxicity is mediated through CDC.

21 It is still a further objective of the instant invention to produce CDMAB whose  
22 cytotoxicity is a function of their ability to catalyze hydrolysis of cellular chemical bonds.

1           A still further objective of the instant invention is to produce CDMAB which are useful  
2   for in a binding assay for diagnosis, prognosis, and monitoring of cancer.

3           Other objects and advantages of this invention will become apparent from the  
4   following description wherein are set forth, by way of illustration and example, certain  
5   embodiments of this invention.

6   Brief Description of the Figures:

7           The patent or application file contains at least one drawing executed in color.  
8   Copies of this patent or patent application publication with color drawing(s) will be  
9   provided by the Office upon request and payment of the necessary fee.

10   Figure 1. Histogram showing mean body weight of the different treatment groups over the  
11   duration of the study. Data are presented as the mean +/- SEM for each group at each time  
12   point.

13   Figure 2. Effect of H460-16-2 on tumor growth in a preventative MB-231 breast cancer  
14   model. The dashed line indicates the period during which the antibody was administered. Data  
15   points represent the mean +/- SEM.

16   Figure 3. Survival of tumor-bearing mice after treatment with H460-16-2, buffer and isotype  
17   control antibody. Mice were monitored for survival for over 70 days post-treatment.

18   Figure 4. Effect of H460-16-2 on tumor growth in an established MDA-MB-231 breast cancer  
19   model. The dashed line indicates the period during which the antibody was administered. Data  
20   points represent the mean +/- SEM.

21   Figure 5. Graphical representation of treatment efficacy or the anti-tumor effect of ARH460-  
22   16-2, and Cisplatin. Growth inhibition was calculated as a ratio of the median tumor volume of



1 treated versus the isotype control treated group in percent:  $T/C \times 100$ , where T is the median  
2 tumor of the treated group and C the median tumor volume of the control group on day X. The  
3 dashed line indicates period of treatment.

4 Figure 6: Mean body weights of the animals in the study groups before and after the treatment  
5 period.

6 Figure 7. Survival of tumor-bearing mice after treatment with H460-16-2, Cisplatin or isotype  
7 control antibody. Mice were monitored for survival for over 60 days post-treatment.

8 Figure 8. Human MB-231 Breast Cancer Explanted from a SCID Mouse. A. Anti-vimentin. B.  
9 H460-16-2. C. Anti-gp96. Arrow points to cells with cytoplasmic and punctate staining.  
10 Magnification is 100X.

11 Figure 9. Mouse Liver. A. Anti-vimentin. B. H460-16-2. C. Anti-gp96. Note positive staining  
12 by anti-gp96 of hepatocytes. Magnification is 100X.

13 Figure 10. Mouse Kidney A. Anti-vimentin. B. H460-16-2. Arrow points to apical staining of  
14 tubular cells. C. Anti-gp96. Arrow points to diffuse staining of tubular cells. Magnification is  
15 100X.

16 Figure 11. Mouse Ovary A. Anti-vimentin. B. H460-16-2. Arrow points to cytoplasmic staining  
17 of ova in the follicle. C. Anti-gp96. Arrow points to granulosa cells. Magnification is 100X.

18 Figure 12. Representative micrograph of H460-16-2 binding to breast cancer tumor  
19 (infiltrating duct carcinoma). The yellow and orange arrows in panel point to stromal cells and  
20 sheets of malignant cells respectively. Magnification is 100X.

21 Figure 13. Representative micrographs showing the binding pattern obtained with H460-16-2  
22 (A) and the anti-gp96 antibody (B) on tissues sections of infiltrating duct carcinoma samples  
23 from a breast cancer tissue array. Blue arrows indicate cellular localization of the antigenic

1 target. Magnification is 200X.

2

3 Detailed Description Of The Invention:

4 Example 1

5 The hybridoma cell line H460-16-2 was deposited, in accordance with the Budapest  
6 Treaty, with the American Type Culture Collection, 10801 University Blvd., Manassas, VA  
7 20110-2209 on September 4, 2002, under Accession Number PTA-4621. In accordance with  
8 37 CFR 1.808, the depositors assure that all restrictions imposed on the availability to the  
9 public of the deposited materials will be irrevocably removed upon the granting of a patent.

10 H460-16-2 monoclonal antibody was produced by culturing the hybridomas in CL-  
11 1000 flasks (BD Biosciences, Oakville, ON) with collections and reseeding occurring  
12 twice/week and was purified according to standard antibody purification procedures with  
13 Protein G Sepharose 4 Fast Flow (Amersham Biosciences, Baie d'Urfé, QC).

14

15 In Vivo Preventative Tumor Experiments

16 With reference to the data shown in Figures 1 and 2, 4 to 8 week old, female SCID  
17 mice were implanted with 5 million MB-231 human breast cancer cells in 100 microliters  
18 saline injected subcutaneously in the scruff of the neck. The mice were randomly divided into  
19 3 treatment groups of 10. On the day prior to implantation 20 mg/kg of H460-16-2 test  
20 antibody, antibody buffer or isotype control antibody (known not to bind MB-231 cells) was  
21 administered intraperitoneally at a volume of 300 microliters after dilution from the stock  
22 concentration with a diluent that contained 2.7 mM KCl, 1 mM KH<sub>2</sub>PO<sub>4</sub>, 137 mM NaCl and

1 20 mM Na<sub>2</sub>HPO<sub>4</sub>. The antibodies were then administered once per week for a period of 7  
2 weeks in the same fashion.

3 Tumor growth was measured roughly every 7th day with calipers for up to 10 weeks or  
4 until individual animals reached the Canadian Council for Animal Care (CCAC) end-points or  
5 day 120. Body weights of the animals were recorded for the duration of the study. At the end  
6 of the study all animals were euthanised according to CCAC guidelines.

7 The data presented in this study is a typical example of a longitudinal data set.  
8 Usually, in such data sets there are high correlations among time-points and higher correlations  
9 are observed between closer time-points. Because of this, *repeated measures analysis of*  
10 *variance* (Rep. ANOVA) was used to determine the differences among treatments and the  
11 method of *analysis of covariance* was used to determine the time-points when differences  
12 occurred. The latter is a suitable method when the differences among groups at each time-  
13 point may not be just due to groups but may be due to the previous time-points.

14 There were no clinical signs of toxicity throughout the study. Body weight measured at  
15 weekly intervals was a surrogate for well-being and failure to thrive. Figure 1 represents the  
16 mean body weight of mice for the 3 groups over the study period. Body weights within each  
17 group increased over time. Rep. ANOVA indicated that there was no significant difference  
18 among groups and the mean profiles do not differ over time-points for the groups treated with  
19 isotype control, antibody buffer or H460-16-2.

20 Using Rep. ANOVA for the whole experiment, the following results were noticeable.  
21 The Rep. ANOVA method indicated that not only the means of the groups were different ( $p <$   
22 0.001) but also the shapes of the mean profiles differed from each other. As can be seen in  
23 Figure 2, treatment group H460-16-2 seemed to have a superior effect compared to the other

1 groups. In addition, the difference between the isotype control treated group and the antibody  
2 buffer treated group was not statistically significant. From *analysis of covariance*, significant  
3 differences occurred for the first time at day 18, where isotype and buffer treatment groups  
4 differed from the H460-16-2 treatment group. At day 53, (the first tumor volume  
5 measurement after the cessation of treatment) tumor volume of the group treated with H460-  
6 16-2 was 1.3% of the antibody control treated group ( $p < 0.0001$ ) thereby demonstrating  
7 effectiveness at preventing tumor burden. There was also a corresponding survival benefit  
8 (Figure 3) from treatment with H460-16-2. Enhanced survival is a valuable indicator of  
9 efficacy. All 3 groups were followed for over 70 days post-treatment. The Cox proportional  
10 hazard test estimates that the risk of dying in the ARH460-16-2 group was about 71% of the  
11 buffer control group ( $p = 0.028$ ). These data demonstrate that treatment with the test antibody  
12 confers a survival benefit compared to control-treated groups. Control groups reached 50%  
13 mortality between day 74-81 post-implantation. In contrast, treated groups had not reached  
14 50% mortality at the time of termination of the study (day 120 post-implantation). The isotype  
15 control group treatment group reached 100% mortality by day 74 post-implantation. In  
16 contrast, H460-16-2 treated animals displayed 60% survival at the end of the study.

17 In summary, H460-16-2 antibody treatment prevented tumor burden and increased  
18 survival in comparison to a control antibody in a well-recognized model of human cancer  
19 disease. These results suggest a potential pharmacologic and pharmaceutical benefit of this  
20 antibody (H460-16-2) as a therapy in other mammals, including man.

21

## 22 Example 2

### 23 In Vivo Established Tumor Experiments:

1 Female SCID mice, 5 to 6 weeks old, were implanted with 5 million MB-231 breast  
2 cancer cells in 100 microliters saline injected subcutaneously in the scruff of the neck. Tumor  
3 growth was measured with calipers every week. When the majority of the cohort reached a  
4 tumor volume of 100 mm<sup>3</sup> (range 70-130 mm<sup>3</sup>) at 34 days post implantation, 12 mice were  
5 randomized into each of four treatment groups. H460-16-2 or isotype control antibody (known  
6 not to bind MB-231 cells) was administered intravenously with 15 mg/kg/dose at a volume of  
7 150 microliters after dilution from the stock concentration with a diluent that contained 2.7  
8 mM KCl, 1 mM KH<sub>2</sub>PO<sub>4</sub>, 137 mM NaCl and 20 mM Na<sub>2</sub>HPO<sub>4</sub>; cisplatin was administered at  
9 9 mg/kg/dose (diluted in saline) intraperitoneally in 300 microliters. The antibodies were then  
10 administered 3 times per week for a total of 10 doses in the same fashion until day 48 post-  
11 implantation. Cisplatin was administered every four days for 3 doses. Tumor growth was  
12 measured around every 7th day with calipers for the duration of the study or until individual  
13 animals reached CCAC end-points. Body weights of the animals were recorded for the  
14 duration of the study. At the end of the study all animals were euthanised according to CCAC  
15 guidelines.

16 At the time of randomization the mean tumor volumes and the standard deviations in  
17 each group were similar: isotype control, (97.60+/-18.33); H460-16-2 (95.25+/-16.82);  
18 cisplatin (98.00+/-18.93). This indicated that true randomization had occurred. As shown in  
19 Figure 4 the antibody H460-16-2 was able to significantly suppress tumor growth at the end of  
20 the 3-week treatment period. Comparisons of the mean tumor volume between the 3 groups  
21 showed the differences between the groups were highly significant (Table 1).

22

23

Table 1: Mean Tumor Volume Comparison At End Of Treatment

Group (1)	Group (2)	Mean Difference (1-2)	Std. Error	Sig.
Isotype	H460-16-2	187.58*	41.09	0
	Cisplatin	300.69*	43.1	0
H460-16-2	Isotype	187.58*	41.09	0
	Cisplatin	113.12*	43.1	0.012
Cisplatin	Isotype	300.69*	43.1	0
	H460-16-2	113.12*	43.1	0.012

\*The mean difference is significant at the 0.05 level.

Further evaluation of efficacy was assessed by calculating T/C (median tumor volume of treated (T) versus the median tumor volume of isotype control (C) in a percent) ratios which reflect growth inhibition. H460-16-2 antibody achieved an endpoint of median T/C tumor volume equal to 49% (Figure 5). Figure 4 further shows that H460-16-2 treatment resulted in marked suppression of tumor growth when compared to the isotype control and that the suppression was 2/3 that of cisplatin given at its maximum tolerated dose (MTD) but without cisplatin's accompanying toxicity or death.

Body weights recorded weekly for the duration of the experiment were used as a surrogate for evaluation of safety and toxicity. As outlined in Table 2 and displayed in Figure 6, there was a minimal difference in weight for the groups treated with the isotype control or H460-16-2. In contrast, during the treatment period, there was significant ( $p=0.0005$ ) cachexia observed in the cisplatin group. In this group, weight loss reached 19.2% of the initial body weight and additional evidence of clinical distress such as ruffled fur, skin tenting due to dehydration and lethargy occurred. There were no deaths in the H460-16-2 treated group

1 compared to 2 deaths observed in the cisplatin treated group.

4 Table 2: Changes In Body Weight And Tumor Growth Suppression (%T/C) At End Of Treatment

Therapeutic Agent	No./Group	Dose	% Body Weight Change	% Tumor Growth Suppression
Isotype Control	12	15 mg/kg/dose*	no mean change	
H460-16-2	12	15 mg/kg/dose*	-2.30%	49
Cisplatin	12 (-2)	9 mg/kg/dose**	-19.20%	25

12 \* Dose administered i.v. 3 x per week for 3 weeks.

12 \*\* Dose administered i.p. 1 x every 4 days for 3 doses.

13 H460-16-2 showed a survival benefit in comparison to treatment with isotype control  
14 (Figure 7). By day 170 (around 120 days post-treatment), 33 percent of the H460-16-2  
15 treatment group was still alive compared to 0 percent for both the cisplatin and isotype control  
16 groups.

17 In summary, H460-16-2 is significantly more effective than the isotype control  
18 antibody in suppressing tumor growth in an established tumor xenograft model of breast  
19 cancer in SCID mice. Over the 3-week treatment period, H460-16-2 achieved an endpoint of  
20 median T/C tumor volumes of less than 50% relative to control. In addition, H460-16-2  
21 resulted in suppression that was two thirds that of cisplatin given at MTD but without the signs  
22 of toxicity or death observed with the chemotherapeutic drug.

23 Therefore treatment with H460-16-2 significantly decreased the tumor burden of  
24 established tumors in comparison to a control antibody and showed survival benefits in a well-  
25 recognized model of human cancer disease suggesting pharmacologic and pharmaceutical  
26 benefits of this antibody for therapy in other mammals, including man.

1

2 Example 3

3 Normal Mouse Tissue Staining

4       The distribution of the H460-16-2 antigen was studied in mouse tissues and compared  
5 to the gp96 antigen. IHC optimization studies were initially performed in order to determine  
6 the conditions for further experiments. H460-16-2 monoclonal antibody was produced and  
7 purified as stated above.

8       An untreated mouse implanted sub-cutaneously with MB-231 tumor cells was  
9 euthanised 74 days post-implantation. Tumor tissue and tissue from major organs were  
10 dissected out and fixed in 10% neutral buffered formalin for 48 hours. Following fixation, the  
11 tissues were transferred to 70% ethanol, processed, paraffin-embedded, sectioned and mounted  
12 on glass slides for staining. Slides were deparaffinized by drying in an oven at 60 °C for 1  
13 hour and dewaxed by immersing in xylene 5 times for 4 minutes each in Coplin jars.  
14 Following treatment through a series of graded ethanol washes (100%-75%) the sections were  
15 re-hydrated in water. The slides were immersed in 10 mM citrate buffer at pH 6 (Dako,  
16 Toronto, ON) then microwaved at high, medium, and low power settings for 5 minutes each  
17 and finally immersed in cold PBS. Slides were then immersed in 3% hydrogen peroxide  
18 solution for 6 minutes, washed with PBS three times for 5 minutes each, dried, incubated with  
19 Universal blocking solution (Dako, Toronto, ON) for 5 minutes at room temperature, and  
20 dried. H460-16-2, monoclonal mouse anti-vimentin (Dako, Toronto, ON) and anti-grp94, also  
21 known as anti-gp96, (Stressgen Biotechnologies, Victoria, BC) were diluted in antibody  
22 dilution buffer (Dako, Toronto, ON) to its working concentration (either 2.5µg/mL, 5µg/mL or  
23 10µg/mL for each antibody) and incubated overnight in a humidified chamber at 4° C. The



1 slides were washed with PBS 3 times for 5 minutes each. Immunoreactivity of the primary  
2 antibodies was detected/visualized with HRP conjugated secondary antibodies as supplied  
3 (Dako Envision System, Toronto, ON) for 30 minutes at room temperature. Following this  
4 step the slides were washed with PBS 3 times for 5 minutes each and a color reaction  
5 developed by adding DAB (3,3'-diaminobenzidine tetrahydrachloride, Dako, Toronto, ON)  
6 chromogen substrate solution for immunoperoxidase staining for 10 minutes at room  
7 temperature. Washing the slides in tap water terminated the chromogenic reaction. Following  
8 counterstaining with Meyer's Hematoxylin (Sigma Diagnostics, Oakville, ON), the slides were  
9 dehydrated with graded ethanols (75-100%) and cleared with xylene. Using mounting media  
10 (Dako Faramount, Toronto, ON) the slides were coverslipped. Slides were microscopically  
11 examined using an Axiovert 200 (Zeiss Canada, Toronto, ON) and digital images acquired and  
12 stored using Northern Eclipse Imaging Software (Mississauga, ON). Results were read, scored  
13 and interpreted by a pathologist.

14       The optimum concentration was the one that produced the expected results for the  
15 positive (anti-gp96) and negative control antibodies (anti-vimentin). The anti-vimentin  
16 antibody has been shown to be negative on mouse tissue but positive on human tissue. The  
17 anti-gp96 antibody has previously been shown to be positive on both mouse and human tissue.  
18 In these studies both the high and low concentrations did not produce the expected results with  
19 the control antibodies, but the 5 µg/mL concentration did.

20

21

22

23

Table 3: IHC Of Engrafted MB-231 and SCID Mouse Tissue

Tissue	Anti-vimentin	H460-16-2	Anti-gp96
MB-231	+++ MB-231 (M/C)	+++ MB-231 (M)	++ MB-231 (C/P)
Liver	-	-	+++ hepatocytes (C)
Pancreas	-	-	++ Islets of Langerhans (C/P)
Spleen	-	-	-
Heart	-	-	-
Adipose Tissue	-	-	-
Lung	+++ Metastatic MB-231 (C)	+ Metastatic MB-231 (M)	+ Metastatic MB-231 (C)
Kidney	-	+++ DCT+PCT (A)	++ DCT+PCT (C/D/P)
Brain	-	-	+ Astrocytes (C/P) (Cerebrum)
Ovary	-	++ Ova (C/N)	+++ Zona Granulosa (C/P) Ova (C/N/D)
Fallopian Tubes	-	-	++ Mucosal epithelium (C/A)

1

2

3 Abbreviations are-M: Membrane staining; C: Cytoplasmic staining; M/C: Membrane-cytoplasmic staining; N:  
4 Nuclear staining; D: Diffuse staining; P: Punctate staining; A: Apical staining; DCT: Distal convoluted tubule;  
5 PCT: Proximal convoluted tubule.

6

7 The results of an IHC survey of SCID mouse tissue and engrafted human breast cancer,  
8 MB-231 (Table 3) shows the negative control antibody anti-vimentin is negative for mouse  
9 tissue but positive for human tissue. Anti-vimentin (Figure 8A) shows intense cytoplasmic and  
10 some membranous staining; H460-16-2 shows intense membranous staining (Figure 8B), and

1 anti-gp96 shows occasional positive punctate and cytoplasmic staining cells (Figure 8C). Anti-  
2 vimentin (Figure 9A) and H460-16-2 (Figure 9B) did not stain mouse liver but anti-gp96  
3 produced intense cytoplasmic staining of hepatocytes (Figure 9C). Anti-vimentin (Figure 10A)  
4 did not stain mouse kidney. H460-16-2 (Figure 10B) showed apical staining of the proximal  
5 and distal convoluted tubules while anti-gp96 produced diffuse staining of the same cells with  
6 a cytoplasmic and punctate pattern (Figure 10C). Anti-vimentin (Figure 11A) did not stain  
7 mouse ovary. H460-16-2 (Figure 11B) showed cytoplasmic and nuclear staining of only the  
8 ova while anti-gp96 produced diffuse cytoplasmic and nuclear staining of the ova and  
9 cytoplasmic and punctate staining of granulosa cells (Figure 11C).

10 The anti-vimentin negative control antibody gave the expected staining of human  
11 tissues and lack of staining of mouse tissues (see Figures 8-11). The anti-gp96 antibody was  
12 used as a positive control because of the likelihood that the H460-16-2 antigen is a cancer  
13 variant of gp96. The anti-gp96 antibody did show staining of MB-231 cells (Figure 8) which is  
14 consistent with the association of gp96 expression with breast cancer. Gp96 was also  
15 expressed in the cytoplasm of many cell types involved with protein synthesis such as  
16 hepatocytes, cells of the Islets of Langerhans in the pancreas, ovarian granulosa cells and the  
17 ova, and mucosal epithelium in the fallopian tubes (Table 3). This is entirely consistent with  
18 the putative role for gp96 as an endoplasmic reticular chaperone protein.

19 H460-16-2 antibody stained MB-231 cells which is consistent with its *in vivo* effects in  
20 the corresponding tumor model. In addition it stained the DCT and PCT in the mouse kidney  
21 (Table 3) as well as the mouse ova (Figure 11). From this sampling of mouse tissues it would  
22 appear that the H460-16-2 antigen is not restricted to just human cells but is also expressed in  
23 the mouse in such a way that the antibody can recognize the antigen. Significantly there are

1 differences in the expression of the H460-16-2 and gp96 antigen as demonstrated with the  
2 staining of normal mouse kidney tissue; apical staining was obtained with H460-16-2 while  
3 diffuse staining was seen with anti-gp96 (Figure 10). Another example of this is the additional  
4 staining of the ova with anti-gp96 (Figure 11). A key difference is that H460-16-2 staining  
5 does not occur in the liver, while gp96 staining is quite extensive (Figure 9).

6 In order to further the experiments described above, H460-16-2, anti-gp96 (for  
7 comparison to H460-16-2) and anti-vimentin (negative control) was used to stain a normal  
8 mouse tissue array (Imgenex, San Diego, CA). The staining procedure used was the same as  
9 stated above. As summarized in Table 4, anti-vimentin did not stain any of the tissues tested;  
10 H460-16-2 again stained only the ovary and kidney while anti-gp96 continued to stain a much  
11 broader range of mouse tissues. These results are consistent with those stated above and again  
12 demonstrates that H460-16-2 expression is not limited to human cells and that its expression is  
13 restricted and specific on normal mouse tissue. It also confirms that H460-16-2 stains the  
14 same tissues as anti-gp96 but anti-gp96 continued to stain a much broader range of tissues  
15 supporting the idea that the H460-16-2 antigen may be a subset of gp96.

16

17

18

19

20

21

22

23

Table 4: IHC on Normal Mouse Tissue Array

	Tissue	Anti-vimentin	H460-16-2	Anti-gp96
1	Skin	-	-	-
2	Skin	-	-	-
3	Spleen	-	-	+/(Lymphocytes)
4	Spleen	-	+/(Lymphocytes)	+/(Lymphocytes)
5	Skeletal Muscle	-	-	-
6	Lung	-	-	-
7	Lung	-	-	-
8	Heart	-	-	-
9	Heart	-	-	-
10	Salivary gland	-	-	+/(Acinar epith.)
11	Liver	-	-	++(Hepatocytes)
12	Liver	-	-	++(Hepatocytes)
13	Gall bladder	- (NR)	- (NR)	- (NR)
14	Pancreas	-	-	+(Acinar epith.)
15	Esophagus	-	-	+(Ganglion cells.)
16	Stomach	-	-	++(Gastric gland epith.)
17	Stomach	-	-	++(Gastric gland epith.)
18	Small bowel	-	-	++(Mucosal epith. & lymphocytes/macrophages)
19	Small bowel	-	-	++(Mucosal epith. & lymphocytes/macrophages in lamina propria)
20	Colon	-	-	++(Mucosal epith. & lymphocytes/macrophages in lamina propria)
21	Colon	-	-	++(Mucosal epith. & lymphocytes/macrophages in lamina propria)
22	Kidney	-	++(Tubular epith)	++(Tubular epith)
23	Kidney	-	+++ (Tubular epith)	++(Tubular epith)
24	Uterus	-	-	-
25	Uterus	-	-	+++ (Endometrial mucosal epith. & glands)
26	Ovary	-	+(ova)	+++ (Ova & zona granulosa)
27	Adrenal	-	-	++(Endocrine cells)
28	Thymus	- (NR)	- (NR)	- (NR)
29	Brain	-	-	-
30	Brain	-	-	-
31	Small bowel	-	-	-

2

3 Abbreviations: NR: Non-representative photo.

1    Example 4

2    Normal Human Tissue Staining

3            IHC studies were conducted to characterize H460-16-2 antigen distribution in humans.

4        It was compared to an antibody directed against gp96 since the H460-16-2 antigen may be a  
5        cancer variant of gp96 as determined previously by biochemical methods. Binding of  
6        antibodies to 60 normal human tissues was performed using a human, normal organ tissue  
7        array (Imgenex, San Diego, CA). All primary antibodies (H460-16-2; anti-grp94 (also known  
8        as anti-gp96, Stressgen Biotechnologies, Victoria, BC); and mouse IgG<sub>1</sub> negative control  
9        (Dako, Toronto, ON)) were diluted in antibody dilution buffer (Dako, Toronto, ON) to a  
10       concentration of 5 µg/ml (found to be the optimal concentration in optimization steps). The  
11       negative control antibody has been shown to be negative to all mammalian tissues by the  
12       manufacturer. The procedure for IHC from Example 3 was followed.

13           Table 5 presents a summary of the results of H460-16-2 staining to an array of normal  
14       human tissues. From the table, there are three categories of tissue staining. A group of  
15       tissues was completely negative. These tissues included normal heart, kidney, brain, pancreas,  
16       breast, testis, ovary and placenta. A second group of tissues comprised tissues that  
17       demonstrated positive staining. These included the skin, ureter, stomach and prostate. The  
18       salivary gland demonstrated the strongest staining with this antibody. A third group of tissues  
19       included tissues in which staining was positive in the tissue section, but was limited to  
20       infiltrating macrophages, lymphocytes and fibroblasts. This included macrophages in the lung,  
21       liver, stomach, intestine and colon, as well as lymphocytes in the spleen and gall bladder. It  
22       should be noted that the antigen is not present on cells in the vital organs, including liver,  
23       kidney, heart and lung. The antibody does bind to macrophages and lymphocytes, and their

1 presence is observed in some of the organs in these sections. In comparison, tissues that were  
2 negative for anti-gp96 included subcutaneous fat, skeletal muscle, lung, heart, stomach smooth  
3 muscle, urinary bladder, myometrium, ovary, placental cord, brain (white and gray matter),  
4 cerebellum, and spinal cord. With the exception of the myometrium, all of these tissues were  
5 also negative for H460-16-2 staining. These results suggest that H460-16-2 binds to a smaller  
6 subset of the tissues recognized by the anti-gp96 antibody. This is consistent with the mouse  
7 tissue study, in which anti-gp96 bound to liver, pancreas, brain and fallopian tubes in addition  
8 to the two tissues that were also bound by H460-16-2, kidney and ovary. These results suggest  
9 that the antigen for H460-16-2 is not widely expressed on normal tissues, and that the antibody  
10 would bind specifically to a limited number of tissues in humans.

Table 5: IHC On Normal Human Tissue With H460-16-2

	Negative	Negative except Macrophages, Lymphocytes, Fibroblasts	Positive
1.	breast	subcutaneous fat	skin, buttock
2.	skeletal muscle	spleen	salivary gland
3.	bronchus	lymph node, mesenteric	stomach, antrum
4.	heart	nasal mucosa	prostate
5.	pancreas	lung	seminal vesicle
6.	stomach smooth muscle	liver	endometrium, secretory
7.	kidney cortex	gallbladder	thyroid
8.	kidney medulla	tonsil	ureter
9.	testis	esophagus	myometrium
10.	epididymis	stomach, body	
11.	endometrium, proliferative	duodenum	
12.	ovary	ileum	
13.	placenta, villi	appendix	
14.	placenta, amniochorion	colon	
15.	placenta cord	sigmoid colon	
16.	adrenal cortex	urinary bladder	
17.	adrenal medulla	uterine cervix (endocervix)	
18.	thymus	uterine cervix (exocervix)	
19.	brain, white matter	salpinx	
20.	brain, gray matter		
21.	cerebellum		
22.	spinal cord		

1

2 To delineate the differences between the distribution of gp96 and the H460-16-2  
3 antigen, the cell types where the antigens are expressed were tabulated in Table 6. From the  
4 table, it is clear that the anti-gp96 antibody binds to a wider range of cell types than H460-16-  
5 2. Further, the strongest binding of H460-16-2 was to fibroblasts, acinar epithelium, and  
6 lymphocytes. There was weak binding to macrophages, keratinocytes, smooth muscle, mucosal  
7 epithelium, and thyroid follicular cells. Anti-gp96 bound to an additional 15 cell types, and to  
8 each cell type that expressed the H460-16-2 antigen. This suggests that the H460-16-2 antigen  
9 is a subset of gp96 since there were no cells that expressed H460-16-2 that did not express the  
10 gp96 antigen.



Table 6: Summary Of IHC on Normal Human Tissues

Cell Type	H460-16-2	Anti-gp96
Fibroblasts	+/++	+
Acinar epithelium	+/++++	+
Lymphocytes	+/++	+/++
Macrophages	+	+
Keratinocytes	+	+
Smooth muscle	+	+
Mucosal epithelium	+	+
Follicular cells	+	+
Lobular epithelium	-	+
Endothelium	-	+
Mucosal glands	-	+
Ductal epithelium	-	+
Hepatocytes	-	++
Acinar cells	-	++
Ganglionic cells	-	+
Villous epithelium	-	+
Loops of Henle	-	+
PCT&DCT	-	+/++
Glandular epithelium	-	+/++/++++
Germinal cells	-	++
Cytotrophoblasts	-	++
Syncytiotrophoblasts	-	++
Granulosa cells	-	+

1

2           These tissue surveys demonstrated that the H460-16-2 antigen has a very limited  
3 distribution in normal tissues including the vital organs. The experiment also showed that the  
4 anti-gp96 antibody bound to a wider range of tissues compared to H460-16-2. H460-16-2  
5 binds to a subset of the tissues bound by anti-gp96 and to limited cell types. In the tissues that  
6 were H460-16-2 positive but not gp96 positive, H460-16-2 bound to only macrophages and  
7 fibroblasts, cell types which generally expressed gp96. The difference between the mouse and  
8 human tissue surveys also point out that the H460-16-2 antibody recognizes an antigen that is  
9 relevant in humans and of limited importance in normal mice since the expression is so  
10 limited. The H460-16-2 antibody itself is applicable in humans since it does recognize the  
11 human form of the antigen.

12

1     Example 5

2     Human Tumor Tissue Staining

3             An IHC study was undertaken to determine the cancer association of the H460-16-2  
4     antigen with human breast cancers and whether the H460-16-2 antibody was likely to  
5     recognize human cancers. A comparison was made for anti-gp96 staining, and an antibody  
6     directed towards *Aspergillus niger* glucose oxidase, an enzyme which is neither present nor  
7     inducible in mammalian tissues (negative control). A breast cancer tissue array derived from  
8     50 breast cancer patients and 9 samples derived from non-neoplastic breast tissue in breast  
9     cancer patients was used (Imgenex Corporation, San Diego, CA). The following information  
10    was provided for each patient: age, sex, American Joint Committee on Cancer (AJCC) tumor  
11    stage, lymph node, estrogen receptor (ER) and progesterone receptor (PR) status. The  
12    procedure for IHC from Example 3 was followed. All antibodies were used at a working  
13    concentration of 5 µg/ml.

14            Tables 7 and 8 provide binding summaries of H460-16-2 and anti-gp96 antibody to a  
15    breast cancer tissue array respectively. Each array contained tumor samples from 50 individual  
16    patients. Overall, 64 percent of the 50 patients tested were positive for H460-16-2 antigen  
17    compared to 84 percent for gp96. For both the H460-16-2 and gp96 antigen, only 2 out of 9  
18    normal breast tissue samples from breast cancer patients were positive. No clear correlation  
19    between estrogen and progesterone receptor status was evident. It also appeared there was a  
20    trend to greater positive expression of the H460-16-2 antigen with higher tumor stage. The  
21    H460-16-2 staining was quite specific for cancerous cells over normal cells as demonstrated in  
22    Figure 12 where stromal cells were clearly negative and sheets of malignant cells were highly  
23    positive. The cellular localization pattern seen with the H460-16-2 antigen was confined to the

1 cell membrane in the majority of cases. The anti-gp96 antibody stained more breast cancer  
2 samples but consistently showed membrane as well as substantial cytoplasmic localization  
3 (Figure 13). Anti-gp96 stained the same samples of normal tissue from breast cancer patients  
4 as H460-16-2. These results suggest the antigen for H460-16-2 may be expressed by almost  
5 two thirds of breast cancer patients. The staining pattern showed that in patient samples, the  
6 antibody is highly specific for malignant cells and the H460-16-2 antigen is localized to the  
7 cell membrane thereby making it an attractive druggable target.

Table 7: IHC With H460-16-2 On Human Normal Breast And Tumor

H460-16-2		Total #	-	+/-	+	++	+++	Total positive	% positive
Patient Samples	Tumor	50	18	13	15	2	2	32	64
	Normal	9	7	0	2	0	0	2	22
ER Status	ER <sup>+</sup>	21	9	5	7	0	0	12	57
	ER <sup>-</sup>	28	8	8	8	2	2	20	71
	Unknown	1	1	0	0	0	0	0	0
PR Status	PR <sup>+</sup>	11	5	2	4	0	0	6	55
	PR <sup>-</sup>	38	12	11	11	2	2	26	68
	Unknown	1	1	0	0	0	0	0	0
AJCC Tumor Stage	T1	7	3	2	2	0	0	4	57
	T2	26	11	5	6	2	2	15	58
	T3	16	4	6	6	0	0	12	75
	T4	1	0	0	1	0	0	1	100

Table 8: IHC With Anti-gp96 On Human Breast Normal And Tumor

Anti-gp96		Total #	-	+/-	+	++	+++	Total positive	% positive
Patient Samples	Tumor	50	8	9	12	9	12	42	84
	Normal	9	7	0	1	1	0	2	22
ER Status	ER <sup>+</sup>	21	6	5	4	3	3	15	71
	ER <sup>-</sup>	28	1	4	8	6	9	27	96
	Unknown	1	1	0	0	0	0	0	0
PR Status	PR <sup>+</sup>	11	4	1	2	2	2	7	64
	PR <sup>-</sup>	38	3	8	10	7	10	35	92
	Unknown	1	1	0	0	0	0	0	0
AJCC Tumor Stage	T1	7	2	2	0	3	0	5	71
	T2	26	5	5	5	5	6	21	81
	T3	16	1	2	6	1	6	15	94
	T4	1	0	0	1	0	0	1	100

1

2 To determine whether the H460-16-2 antigen is expressed on other human tumor  
3 tissues besides breast, H460-16-2 was used on a multiple human tumor tissue array (Imgenex,  
4 San Diego, CA). The following information was provided for each patient: age, sex, organ  
5 and diagnosis. The staining procedure used was the same as the one outlined in Example 3.  
6 Vimentin was used as a positive control antibody and the same negative control antibody was  
7 used as described for the human breast tumor tissue array. All antibodies were used at a  
8 working concentration of 5 µg/mL.

9 As outlined in Table 9, H460-16-2 stained a number of various human cancers besides  
10 breast. The following tumor types were always positive for H460-16-2 (albeit to different  
11 degrees): lymph node (2/2), bone (2/2), lung (4/4), kidney (3/3), uterus (3/3), and thyroid (2/2).  
12 The stomach (4/5), liver (2/3) and parotid gland (2/3) also showed up relatively consistently  
13 positive for staining. Several other tumor types also occasionally stained positive. As seen  
14 with the breast cancers, H460-16-2 staining was localized predominately on the membrane of  
15 cancerous cells.

1           Therefore, it appears that the H460-16-2 antigen is not solely found on the membranes  
2 of breast cancers but also on the membrane of a large variety of tumor types. These results  
3 indicate that H460-16-2 has potential as a therapeutic drug in a wide variety of tumor types  
4 besides breast.

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
  
37  
  
38  
  
39  
  
40  
  
41

2	25	F	Skin	Squamous cell carcinoma	-	+++ M/C	-
3	50	F	Breast	Infiltrating ductal carcinoma	+ Tumor, +++ Stroma	++ Stroma	-
4	57	F	Breast	Invasive papillary carcinoma	+/-	++ Stromal fibroblasts, Blood vessels	-
5	35	F	Breast	Infiltrating lobular carcinoma	+/-	CS	-
6	40	M	Lymph node	Malignant lymphoma, immunoplastic	+++ M	+++ M/C	-
7	58	M	Lymph node	Metastatic adenoma from stomach	+/-	+++ Tumor, Lipocytes	-
8	53	F	Bone	Osteosarcoma	+ M/C	+++ M/C	-
9	26	M	Bone	Giant cell tumor	+ M/C	++ M/C	-
10	40	M	Bone	Chondrosarcoma	CS	CS	CS
11	51	F	Soft tissue	Liposarcoma	-	+++ M/C	-
12	47	F	Soft tissue	Neurofibromatosis	+ M/C	+++ M/C	-
13	74	M	Nasal cavity	Inverted papilloma	++ M	+ Keratin	-
14	57	M	Larynx	Squamous cell carcinoma	+++ M	+++ Stroma	-
15	60	M	Lung	Adenocarcinoma	+/-	++ M/C	-
16	51	F	Lung	Squamous cell carcinoma	+++ M/C	+++ M/C	-
17	68	F	Lung	Adenocarcinoma	+/-	+++ M/C	-
18	60	M	Lung	Small cell carcinoma	+/-	+++ M/C	-
19	88	F	Tongue	Squamous cell carcinoma	+++ M	+++ Stroma	-
20	34	F	Parotid gland	Pleomorphic adenoma	-	++ M/C	-
21	50	F	Parotid gland	Warthin tumor	+++ M/C	+++ Tumor, Lymphocytes	-
22	40	F	Parotid gland	Pleomorphic adenoma	++ M/C	+++ M/C	-
23	56	M	Submandibular gland	Salivary duct carcinoma	-	+++ M/C	-
24	69	F	Liver	Cholangiocarcinoma	+/-	+/- Tumor, +++ Blood vessels	-
25	51	M	Liver	Metastatic gastric carcinoma	-	++ Stroma	-
26	64	M	Liver	Hepatocellular carcinoma	+/-	+/-	-
27	62	F	Gall bladder	Adenocarcinoma	++ Tumor, Lymphocytes	+ Stroma	-
28	64	F	Pancreas	Adenocarcinoma	++ M/C	++ Stroma	-
29	68	M	Esophagus	Squamous cell carcinoma	+/-	++ Stroma	-
30	73	M	Stomach	Adenocarcinoma, poorly differentiated	+ M/C	++ Stroma, Blood vessels	-
31	63	M	Stomach	Adenocarcinoma, moderately differentiated	++ M/C	++ M/C	-
32	59	F	Stomach	Signet ring cell carcinoma	++ M/C	++ M/C	-
33	62	M	Stomach	Malignant lymphoma	+++ M/C	+++ M/C	-
34	51	M	Stomach	Borderline stromal tumor	-	++ M/C	-
35	42	M	Small intestine	Malignant stromal tumor	-	+++ M/C	-
36	52	F	Appendix	Pseudomyxoma peritonii	-	+ Tumor, +++ Lipocytes	-
37	53	M	Colon	Adenocarcinoma	+ M/C	++ Stroma	-
38	67	M	Rectum	Adenocarcinoma	++ M	++ Lipocytes, Blood vessels	-
39	75	F	Kidney	Transitional cell carcinoma	+ M/C	++ Stroma	-
40	54	F	Kidney	Renal cell carcinoma	+/-	++ M	-
41	75	F	Kidney	Renal cell carcinoma	+/-	+ Tumor, +++ Stroma	-
42	65	M	Urinary bladder	Carcinoma, poorly differentiated	++ M/C	++ Stroma	-
43	67	M	Urinary bladder	Transitional cell carcinoma, high grade	-	+++ Stroma, Blood vessels	-
44	62	M	Prostate	Adenocarcinoma	+++ M	+++ Tumor, Stroma, Blood vessels	-
45	30	M	Testis	Seminoma	+/-	+++ Blood vessels	-
46	68	F	Uterus	Endometrial adenocarcinoma	++ Stroma	+ Tumor, +++ Stroma	-
47	57	F	Uterus	Leiomyosarcoma	+ PS	+ M/C	-
48	45	F	Uterus	Leiomyoma	+ C	+++ M/C	-
49	63	F	Uterine cervix	Squamous cell carcinoma	+++ M	+/- Tumor, ++ Stroma	-
50	12	F	Ovary	Endodermal sinus tumor	-	++ Tumor, Stroma	-
51	33	F	Ovary	Mucinous adenocarcinoma	-	++ Stroma	-
52	70	F	Ovary	Fibrosarcoma	-	+++ M/C	-
53	67	F	Adrenal gland	Cortical carcinoma	-	+++ M/C	-
54	61	F	Adrenal gland	Pheochromocytoma	-	+++ M/C	-
55	54	M	Thyroid	Papillary carcinoma	++ M/C	+/- Tumor, ++ Stroma	-
56	58	F	Thyroid	Follicular carcinoma, minimally invasive	++ M	+++ M/C	-
57	74	M	Thymus	Thymoma	+/-	++ M/C	-
58	66	F	Brain	Meningioma	-	+++ M/C	-
59	62	M	Brain	Glioblastoma multiforme	+++ M	++ Tumor, Blood vessels	-

1

2 Table 9: IHC On Human Multi-Tumor Array  
3 Abbreviations: M: Membrane staining; C: Cytoplasmic staining; M/C: Membrane-cytoplasmic staining; CS: The  
4 section is completely sloughed; PS: The section is partially sloughed; F: The section is folded.

5

6 All patents and publications mentioned in this specification are indicative of the levels  
7 of those skilled in the art to which the invention pertains. All patents and publications are  
8 herein incorporated by reference to the same extent as if each individual publication was  
9 specifically and individually indicated to be incorporated by reference.

10 It is to be understood that while a certain form of the invention is illustrated, it is not to  
11 be limited to the specific form or arrangement of parts herein described and shown. It will be  
12 apparent to those skilled in the art that various changes may be made without departing from

1 the scope of the invention and the invention is not to be considered limited to what is shown  
2 and described in the specification. One skilled in the art will readily appreciate that the  
3 present invention is well adapted to carry out the objects and obtain the ends and advantages  
4 mentioned, as well as those inherent therein. Any oligonucleotides, peptides, polypeptides,  
5 biologically related compounds, methods, procedures and techniques described herein are  
6 presently representative of the preferred embodiments, are intended to be exemplary and are  
7 not intended as limitations on the scope. Changes therein and other uses will occur to those  
8 skilled in the art which are encompassed within the spirit of the invention and are defined by  
9 the scope of the appended claims. Although the invention has been described in connection  
10 with specific preferred embodiments, it should be understood that the invention as claimed  
11 should not be unduly limited to such specific embodiments. Indeed, various modifications of  
12 the described modes for carrying out the invention which are obvious to those skilled in the art  
13 are intended to be within the scope of the following claims.

14

15

16

17

18

19

20

21

22

23